These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 10897209)

  • 1. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
    Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
    Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
    Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
    Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biochemical modulation of 5-FU--effect of low dose CDDP].
    Hirata K; Yamamitsu S; Tsuji A; Shirasaka T; Mukaiya M; Oikawa I; Kimura H; Sasaki K; Denno R
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):467-75. PubMed ID: 10097743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
    Kamata T; Hayashi Y; Minatoya G; Michiwa Y; Onishi I; Takeda T; Koyasaki N; Kanno M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1419-22. PubMed ID: 11681250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
    Nakata B; Hirakawa K
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
    Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
    Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma].
    Furuhata T; Hirata K; Yamamitsu S; Kimura H; Sasaki K; Hata F; Shirasaka T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1554-8. PubMed ID: 10553412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
    Asano M; Mori T; Takahashi K; Yasuno M
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):55-60. PubMed ID: 9020946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].
    Maehara Y; Sugimachi K; Kurihara M; Taguchi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):476-85. PubMed ID: 10097744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
    Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
    Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
    Gomi T; Ohtoshi M; Tamaki N; Momoi H; Kanaya S; Katayama T; Wada Y
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):301-4. PubMed ID: 11865638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
    Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.